1.10

0.00% +0.00

After Hours: 1.11 0.01 +0.91%

HCW Biologics Inc (HCWB)

Overview News Price History Financials Discussions Forecast

HCW Biologics Inc stock is currently priced at $1.10, with a 24-hour trading volume of 20,537. It has seen a +0.00% increased in the last 24 hours and a -30.82% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.12 pivot point. If it approaches the $1.08 support level, significant changes may occur.

Previous Close:

$1.10

Open:

$1.1

24h Volume:

20,537

Market Cap:

$41.61M

Revenue:

$2.86M

Net Income/Loss:

$-19.73M

P/E Ratio:

-2.1154

EPS:

-0.52

Net Cash Flow:

$-24.96M

1W Performance:

-2.65%

1M Performance:

-30.82%

6M Performance:

+0.46%

1Y Performance:

-27.63%

1D Range:

$1.10

$1.16

52W Range:

$0.91

$2.32

HCW Biologics Inc Stock (HCWB) Company Profile

Name

HCW Biologics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

954 842 2024

Address

2929 North Commerce Parkway, Miramar

Employee

Twitter

Next Earnings Date

Latest SEC Filings

HCWB's Discussions on Twitter

HCW Biologics Inc Stock (HCWB) Latest News

HCW Biologics Warns of Ability to Continue Operating Without Additional Funds - MarketWatch

MarketWatch

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

GlobeNewswire

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire Inc.

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

GlobeNewswire Inc.

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights - Yahoo Finance

Yahoo Finance

HCWB Stock Quote Price and Forecast - CNN

CNN

HCW Biologics Inc Stock (HCWB) Financials Data

HCW Biologics Inc (HCWB) Revenue 2024

HCWB reported a revenue (TTM) of $2.86 million for the quarter ending September 30, 2023.

HCW Biologics Inc (HCWB) Net Income 2024

HCWB net income (TTM) was -$19.73 million for the quarter ending September 30, 2023, a -55.92% decrease year-over-year.

HCW Biologics Inc (HCWB) Cash Flow 2024

HCWB recorded a free cash flow (TTM) of -$24.96 million for the quarter ending September 30, 2023, a -23.59% decrease year-over-year.

HCW Biologics Inc (HCWB) Earnings per Share 2024

HCWB earnings per share (TTM) was -$0.55 for the quarter ending September 30, 2023, a -53.33% decline year-over-year.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.